Consequently, MGMT promoter methylation was proposed as a prognostic biomarker of the response of GBMs to TMZ [15,16], and quality assured MGMT testing was implemented as a molecular diagnostic method in the 2016 World Health Organization (WHO) classification of brain tumors [17]. The gene discussed is MGMT; the disease is brain neoplasm.